Go Pro
→ Analyst nicknamed “The Prophet” issues new warning for America (From Stansberry Research) (Ad)tc pixel Free EVLO Stock Alerts

Evelo Biosciences (EVLO) Competitors

Evelo Biosciences logo
Compare

EVLO vs. GNCA, PXMD, ARDS, BPTH, and GNCAQ

Should you buy Evelo Biosciences stock or one of its competitors? Evelo Biosciences's main competitors and comparable companies include Genocea Biosciences (GNCA), PaxMedica (PXMD), Aridis Pharmaceuticals (ARDS), Bio-Path (BPTH), and Genocea Biosciences (GNCAQ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Evelo Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Evelo Biosciences Neutral

Evelo Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Evelo Biosciences N/A N/A N/A

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genocea Biosciences has higher revenue and earnings than Evelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

Summary

Genocea Biosciences beats Evelo Biosciences on 6 of the 9 factors compared between the two stocks.

How does Evelo Biosciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Evelo Biosciences Neutral

Evelo Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Evelo Biosciences N/A N/A N/A

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PaxMedica is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

Summary

Evelo Biosciences beats PaxMedica on 6 of the 8 factors compared between the two stocks.

How does Evelo Biosciences compare to Aridis Pharmaceuticals?

Evelo Biosciences (NASDAQ:EVLO) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Evelo Biosciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.310.00

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Aridis Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

Evelo Biosciences has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.95, indicating that its stock price is 4,895% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Evelo Biosciences on 6 of the 6 factors compared between the two stocks.

How does Evelo Biosciences compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Bio-Path has a beta of -0.53, indicating that its stock price is 153% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Bio-Path is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Evelo Biosciences Neutral

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evelo Biosciences' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Evelo Biosciences N/A N/A N/A

Summary

Evelo Biosciences beats Bio-Path on 5 of the 8 factors compared between the two stocks.

How does Evelo Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCAQ) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Genocea Biosciences has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Evelo Biosciences Neutral

0.3% of Evelo Biosciences shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea BiosciencesN/AN/AN/AN/AN/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A N/A N/A
Evelo Biosciences N/A N/A N/A

Summary

Genocea Biosciences and Evelo Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

Get Evelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

EVLO vs. The Competition

Export
MetricEvelo BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2K$12.53B$7.26B$13.10B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio0.00792.39274.9825.77
Price / SalesN/A850.84679.2597.61
Price / CashN/A88.6477.8052.76
Price / BookN/A10.6910.526.34
Net Income-$114.53M$2.83B$3.49B$360.00M

Evelo Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVLO
Evelo Biosciences
N/AN/AN/A-80.0%$2KN/AN/A66
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$6KN/AN/A2
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A-94.1%$5KN/A0.0030
BPTH
Bio-Path
N/A$0.00
flat		N/A-99.2%$5KN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EVLO) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel